Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (25)
Placido Maria Mazzone & Davide Capodanno. (2023) Low dose rivaroxaban for the management of atherosclerotic cardiovascular disease. Journal of Thrombosis and Thrombolysis 56:1, pages 91-102.
Crossref
Crossref
Li Ding, Zhan Shu, Jinbo Hao, Xudong Luo, Xiangdong Ye, Wen Zhu, Wangmei Duan & Zongyun Chen. (2022) Schixator, a new FXa inhibitor from Schistosoma japonicum with antithrombotic effect and low bleeding risk. Biochemical and Biophysical Research Communications 603, pages 138-143.
Crossref
Crossref
Mihailo Nešković, Igor Atanasijević & Predrag Gajin. (2022) Direct oral anticoagulants and peripheral arterial disease. Galenika Medical Journal 1:2, pages 76-79.
Crossref
Crossref
Tomomi Matsuura, Takeshi Soeki, Daiju Fukuda, Etsuko Uematsu, Takeshi Tobiume, Tomoya Hara, Kenya Kusunose, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Tetsuzo Wakatsuki & Masataka Sata. (2021) Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation. Circulation Journal 85:8, pages 1383-1391.
Crossref
Crossref
Sergi Torramade-Moix, Marta Palomo, Manel Vera, Didac Jerez, Ana Belen Moreno-Castaño, M Urooj Zafar, Jordi Rovira, Fritz Diekmann, Joan Carles Garcia-Pagan, Gines Escolar, Aleix Cases & Maribel Diaz-Ricart. (2020) Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. Cardiovascular Drugs and Therapy 35:3, pages 521-532.
Crossref
Crossref
Ewa Wypasek, Joanna Natorska, Piotr Mazur, Magdalena Kopytek, Bogusław Gawęda, Przemysław Kapusta, Jacek Madeja, Teresa Iwaniec, Bogusław Kapelak & Anetta Undas. (2020) Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. Vascular Pharmacology 130, pages 106679.
Crossref
Crossref
Kouhei Nii, Yusuke Takemura, Ritsurou Inoue, Yusuke Morinaga, Takafumi Mitsutake & Toshio Higashi. (2020) Safety of direct oral anticoagulant - and antiplatelet therapy in patients with atrial fibrillation treated by carotid artery stenting. Journal of Stroke and Cerebrovascular Diseases 29:7, pages 104899.
Crossref
Crossref
Ravi S. Keshari, Robert Silasi, Narcis I. Popescu, Constantin Georgescu, Hala Chaaban, Cristina Lupu, Owen J.T. McCarty, Charles T. Esmon & Florea Lupu. (2020) Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. Journal of Thrombosis and Haemostasis 18:1, pages 180-190.
Crossref
Crossref
Styliani Papadaki & Alexandros D. Tselepis. (2019) Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?. Angiology 70:10, pages 896-907.
Crossref
Crossref
Anke C. Fender, Reza Wakili & Dobromir Dobrev. (2019) Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants. Pharmacological Research 145, pages 104257.
Crossref
Crossref
Junhao Xing, Lingyun Yang, Jinpei Zhou & Huibin Zhang. (2018) Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors. Bioorganic & Medicinal Chemistry 26:23-24, pages 5987-5999.
Crossref
Crossref
Hidekazu Kondo, Ichitaro Abe, Akira Fukui, Shotaro Saito, Miho Miyoshi, Kohei Aoki, Tetsuji Shinohara, Yasushi Teshima, Kunio Yufu & Naohiko Takahashi. (2018) Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation. Journal of Cardiology 71:3, pages 310-319.
Crossref
Crossref
Azeemullah A. Syed & Alka Mehta. (2018) Target Specific Anticoagulant Peptides: A Review. International Journal of Peptide Research and Therapeutics 24:1, pages 1-12.
Crossref
Crossref
Safieh Ebrahimi, Sara Rezaei, Parvaneh Seiri, Mikhail Ryzhikov, Seyed Isaac Hashemy & Seyed Mahdi Hassanian. (2017) Factor Xa Signaling Contributes to the Pathogenesis of Inflammatory Diseases. Journal of Cellular Physiology 232:8, pages 1966-1970.
Crossref
Crossref
Yasuo Terayama. (2017) Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients—Analysis of Pharmaceuticals and Medical Devices Agency Data. Journal of Stroke and Cerebrovascular Diseases 26:6, pages 1171-1181.
Crossref
Crossref
Masanori Tsujimoto, Gen Kuroyanagi, Rie Matsushima-Nishiwaki, Yuko Kito, Yukiko Enomoto, Hiroki Iida, Shinji Ogura, Takanobu Otsuka, Haruhiko Tokuda, Osamu Kozawa & Toru Iwama. (2016) Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase. PLOS ONE 11:2, pages e0149077.
Crossref
Crossref
Thati Madhusudhan, Bryce A. Kerlin & Berend Isermann. (2015) The emerging role of coagulation proteases in kidney disease. Nature Reviews Nephrology 12:2, pages 94-109.
Crossref
Crossref
Rick van Gorp & Leon Schurgers. (2015) New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients 7:11, pages 9538-9557.
Crossref
Crossref
Ozlem Gul Utku, Eylem Akbay Karatay, Harun Erdal, Mehmet Arhan, Ibrahim Koral Onal, Mehmet Ibis, Ozgur Ekinci, Canan Yilmaz Demirtas & Selahattin Unal. (2015) Rivaroxaban Induces Mucosal Healing in a Rat Model of Trinitrobenzene Sulfonic Acid-Induced Colitis. Medical Principles and Practice 24:5, pages 470-476.
Crossref
Crossref
Arthur J. Campbell, Michelle L. Lamb & Diane Joseph-McCarthy. (2014) Ensemble-Based Docking Using Biased Molecular Dynamics. Journal of Chemical Information and Modeling 54:7, pages 2127-2138.
Crossref
Crossref
H. M. H. Spronk, A. M. de Jong, H. J. Crijns, U. Schotten, I. C. Van Gelder & H. ten Cate. (2014) Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovascular Research 101:3, pages 344-351.
Crossref
Crossref
Leon Schurgers & Henri Spronk. (2017) Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. Thrombosis and Haemostasis 112:11, pages 909-917.
Crossref
Crossref
Charles T. Esmon. (2017) Targeting factor Xa and thrombin: impact on coagulation and beyond. Thrombosis and Haemostasis 111:04, pages 625-633.
Crossref
Crossref
Meganathan Chandrasekaran, Sugunadevi Sakkiah & Keun Woo Lee. (2011) Combined chemical feature-based assessment and Bayesian model studies to identify potential inhibitors for Factor Xa. Medicinal Chemistry Research 21:12, pages 4083-4099.
Crossref
Crossref
Nicolas Collin, Teresa C.F. Assumpção, Daniella M. Mizurini, Dana C. Gilmore, Angélica Dutra-Oliveira, Michalis Kotsyfakis, Anderson Sá-Nunes, Clarissa Teixeira, José M.C. Ribeiro, Robson Q. Monteiro, Jesus G. Valenzuela & Ivo M.B. Francischetti. (2012)
Lufaxin, a Novel Factor Xa Inhibitor From the Salivary Gland of the Sand Fly
Lutzomyia longipalpis
Blocks Protease-Activated Receptor 2 Activation and Inhibits Inflammation and Thrombosis In Vivo
. Arteriosclerosis, Thrombosis, and Vascular Biology 32:9, pages 2185-2198.
Crossref
Crossref